Supportive Care in Pancreatic
Carcinoma UICC Stages I-IV Patients Treated with Fermedted Mistletoe (Viscum
Album L.) Extract
P. Heusser MD, MME, H. Matthes
MD, W.E. Friedel MD, P.R. Bock MD
A multicenter epidemiological
observational cohort study on 396 (201 Iscador and 195 control) evaluable
patients from 17 centers. In comparison to a parallel control group, the Iscador
group showed significantly fewer ADRs of the conventional therapies, fewer
disease and therapy-related symptoms and longer overall survival. The Iscador
treatment was well tolerated and appears beneficial in the supportive care pf
patients with pancreatic carcinoma.
Pan.Ca-Poster_SIO_2007_red.pdf
Note: this poster was presented at the 2007 SIO Conference in S.F. by Dr. Peter Heusser, former Head
of the Lukas Klinik, Arlesheim,
Switzerland; and was reviewed during the panel session at the closing of the
conference.
Please address your questions or
comments to:
Michele Sanz
Medical Division Manager
Weleda North
America
1 Closter
Rd
Palisades, NY
10964
Phone:
1.800.241.1030, ext. 5550
Direct: 1.845.510.5550
Cell: 1.845.480.2260
Fax: 1.845.365.8260 /
michele@weleda.com